Coronary stents (CS) are expandable tubular metallic implants that are inserted into coronary arteries that have stenosis as a result of underlying atherosclerosis. A percutaneous coronary intervention (PCI) or coronary angioplasty with stent implantation is the name given to this revascularization treatment. The coronary stent was first developed in the 1980s, and it has since evolved in terms of shape, structure, and material employed. Balloon angioplasty, which used an inflating balloon-tipped catheter placed percutaneously through an arterial entry point in the limb and advanced into the coronary arteries, was the basis of coronary revascularization before the advent of stents.
With the introduction of totally dissolving stents, the coronary
stent market is entering a new era of technological
advancements. Abbott (US) got FDA approval to commercialize its Absorb
bioresorbable cardiac stent in July 2016. Absorb is the first and only totally
dissolving stent to be authorized for the treatment of coronary artery disease.
For the treatment of CAD, researchers have also created dual-therapy stents and
bioengineered stents.
A coronary stent is a tiny, expandable tube-shaped device
that is inserted into the heart's coronary arteries. Percutaneous coronary
intervention (PCI) procedures use coronary stents to treat patients with
coronary artery disease (CAD). They're utilised to treat de novo lesions,
small-vessel disease (SVD), bifurcation lesions, and tortuous and narrow
lesions in coronary artery disease.
The market is divided into two types of stents based on how they are delivered: balloon expandable stents and self-expanding stents. Due to increased research activities to improve this technology, high use of these stents, and growing regulatory approvals for balloon-expandable stents, the balloon expandable stents segment is predicted to grow at the greatest CAGR throughout the projection period.